EICHORPublic-registry site landscape for NCT01639248, “Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC”, a Triple Negative Breast Cancer study sponsored by CASI pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01639248 (registry record) |
| Study title | Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC |
| Official title | A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer |
| Sponsor | CASI pharmaceuticals, Inc. |
| Condition(s) | Triple Negative Breast Cancer |
| Phase | PHASE2 |
| Listed sites | 3 |
| Intervention(s) | ENMD-2076 |
| Site countries | United States, China |
Patient-friendly overview of this study: eichor.com/study/NCT01639248.
Eichor generates a preliminary site-risk snapshot for NCT01639248 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
